Conditions: Non-Squamous Non-Small Cell Lung Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 485
Healthy volunteers: no

Brief summary:
This open-label, randomized, multicenter study will evaluate the efficacy and safety of bevacizumab (Avastin) in combination with standard of care (SOC) treatment in participants with advanced non-squamous NSCLC. Participants will be enrolled at documentation of progression of disease (PD) after 4-6 cycles of first-line treatment with bevacizumab plus a platinum doublet-containing therapy and a minimum of two cycles of bevacizumab maintenance treatment prior to PD. Participants will be randomly assigned to one of two treatment arms to receive either bevacizumab plus SOC treatment or SOC treatment alone.

Detailed description:

Arms:
arm 1: Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first). arm 2: Participants will receive investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).

Interventions: intervention 1: Bevacizumab intervention 2: Docetaxel intervention 3: Erlotinib intervention 4: Pemetrexed
Intervention descriptions: intervention 1: Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously. intervention 2: Docetaxel 60 or 75 milligram per meter square (mg/m\^2) on Day 1 every 21 days. intervention 3: Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food. intervention 4: Pemetrexed 500 mg/m\^2 IV over 10 minutes on Day 1 every 21 days.

Protocol document: